| DRUG | SUPPLIED | DOSE | COMMENTS |
|---|---|---|---|
| SUMATRIPTAN (Paeds) (Imitrex) Mechanism of action: Sumatriptan is a Serotonin receptor agonist and its primary therapeutic effect is in its inhibition of the release of Calcitonin gene-related peptide. It is used in the preventative treatment of migraine. It also decreases the activity of the trigeminal nerve, accounting for its efficacy in treating cluster headaches Ref: 7, 44, 483, 545, 546 1. Oskoui M. et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents. Neurology. 2019;93:489-499 2. Wang G; Tan T; Liu Y; Hong P. Drugs for acute attack of pediatric migraine: A network meta-analysis of randomized controlled trials. Clinical Neurology and Neurosurgery 195 (2020) 105853 Last update: 2022-04-24 |
injectable: 6 mg/ 0.5 mL tablet: 25 mg, 50 mg, 100 mg |
Children 6-18 years 0.06 mg/kg/dose SC x 1 dose (Max 6 mg/dose) Children 8-12 years 25-50 mg/dose PO x 1 dose Adolescents greater than 12 years 25-100 mg/dose PO x 1 dose |
SC use only; do not administer IM. Do not administer IV (may cause coronary vasospasm). Efficacy of oral sumatriptan not well established in children. Adverse effects appear to be dose-related. Swallow tablet whole; do not split tablet. Standard Prescription: Sumatriptan __mg SC one dose ( __mg/kg/dose) Sumatriptan __mg PO one dose ( __mg/kg/dose) |